Michael Tesar
Overview
Explore the profile of Michael Tesar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
185
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Muller T, Tasser C, Tesar M, Fucek I, Schniegler-Mattox U, Koch J, et al.
MAbs
. 2023 Aug;
15(1):2245519.
PMID: 37599441
A challenge when developing therapeutic antibodies is the identification of candidates with favorable pharmacokinetics (PK) early in development. A key determinant of immunoglobulin (IgG) serum half‑life is the efficiency of...
2.
Kvasnak E, Magyarova E, Domankus M, Tesar M, Kymplova J, Fetissov V, et al.
Behav Sci (Basel)
. 2023 Jan;
13(1).
PMID: 36661611
Working memory is a cognitive process that involves short-term active maintenance, flexible updating, and processing of goal- or task-relevant information. All frequency bands are involved in working memory. The activities...
3.
Reusch U, Ellwanger K, Fucek I, Muller T, Schniegler-Mattox U, Koch J, et al.
Antibodies (Basel)
. 2022 Feb;
11(1).
PMID: 35225870
Innate cell engager (ICE) constructs are bispecific tetravalent antibodies targeting specific tumor antigens and simultaneously engaging natural killer (NK) cell and macrophage receptors for the destruction of tumor cells. Pre-complexing...
4.
Slavetinsky C, Hauser J, Gekeler C, Slavetinsky J, Geyer A, Kraus A, et al.
Elife
. 2022 Jan;
11.
PMID: 35044295
The pandemic of antibiotic resistance represents a major human health threat demanding new antimicrobial strategies. Multiple peptide resistance factor (MprF) is the synthase and flippase of the phospholipid lysyl-phosphatidylglycerol that...
5.
Wingert S, Reusch U, Knackmuss S, Kluge M, Damrat M, Pahl J, et al.
MAbs
. 2021 Jul;
13(1):1950264.
PMID: 34325617
Epidermal growth factor receptor (EGFR)-targeted cancer therapy such as anti-EGFR monoclonal antibodies and tyrosine kinase inhibitors have demonstrated clinical efficacy. However, there remains a medical need addressing limitations of these...
6.
Ellwanger K, Reusch U, Fucek I, Wingert S, Ross T, Muller T, et al.
MAbs
. 2019 Jun;
11(5):899-918.
PMID: 31172847
Redirection of immune cells to efficiently eliminate tumor cells holds great promise. Natural killer cells (NK), macrophages, or T cells are specifically engaged with target cells expressing markers after infection...
7.
Koch J, Tesar M
Transfus Med Hemother
. 2017 Oct;
44(5):337-350.
PMID: 29070979
Immunotherapy has the potential to support and expand the body's own armamentarium of immune effector functions, which have been circumvented during malignant transformation and establishment of cancer and is presently...
8.
Ellwanger K, Reusch U, Fucek I, Knackmuss S, Weichel M, Gantke T, et al.
Front Oncol
. 2017 Jun;
7:100.
PMID: 28596941
To harness the cytotoxic capacity of immune cells for the treatment of solid tumors, we developed tetravalent, bispecific tandem diabody (TandAb) antibodies that recognize EGFRvIII, the deletion variant III of...
9.
Boute N, Lowe P, Berger S, Malissard M, Robert A, Tesar M
Front Pharmacol
. 2016 Mar;
7:27.
PMID: 26924984
Based on the recent development of NanoLuc luciferase (Nluc), a small (19 kDa), highly stable, ATP independent, bioluminescent protein, an extremely robust and ultra high sensitivity screening system has been...
10.
Nagy Z, Hubner B, Lohning C, Rauchenberger R, Reiffert S, Thomassen-Wolf E, et al.
Nat Med
. 2002 Jul;
8(8):801-7.
PMID: 12101408
The Human Combinatorial Antibody Library (HuCAL) was screened for antibodies specific to human leukocyte antigen-DR (HLA-DR) that induce programmed death of lymphoma/leukemia cells expressing the target antigen. The active Fab...